Acuity v. Masters Pharmaceuticals, Inc.

2022 Ohio 3092, 205 N.E.3d 460, 169 Ohio St. 3d 387
CourtOhio Supreme Court
DecidedSeptember 7, 2022
Docket2020-1134
StatusPublished
Cited by10 cases

This text of 2022 Ohio 3092 (Acuity v. Masters Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering Ohio Supreme Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Acuity v. Masters Pharmaceuticals, Inc., 2022 Ohio 3092, 205 N.E.3d 460, 169 Ohio St. 3d 387 (Ohio 2022).

Opinion

[Until this opinion appears in the Ohio Official Reports advance sheets, it may be cited as Acuity v. Masters Pharmaceutical, Inc., Slip Opinion No. 2022-Ohio-3092.]

NOTICE This slip opinion is subject to formal revision before it is published in an advance sheet of the Ohio Official Reports. Readers are requested to promptly notify the Reporter of Decisions, Supreme Court of Ohio, 65 South Front Street, Columbus, Ohio 43215, of any typographical or other formal errors in the opinion, in order that corrections may be made before the opinion is published.

SLIP OPINION NO. 2022-OHIO-3092 ACUITY, APPELLANT v. MASTERS PHARMACEUTICAL, INC., APPELLEE. [Until this opinion appears in the Ohio Official Reports advance sheets, it may be cited as Acuity v. Masters Pharmaceutical, Inc., Slip Opinion No. 2022-Ohio-3092.] Insurer of distributor of pharmaceutical products, including prescription opioids, does not owe a duty to defend its insured in lawsuits brought by governmental entities seeking economic damages for losses caused by the opioid epidemic—The insurance policies cover “damages because of bodily injury,” and the damages sought by the governmental entities do not fall within that coverage. (No. 2020-1134—Submitted September 8, 2021—Decided September 7, 2022.) APPEAL from the Court of Appeals for Hamilton County, No. C-190176, 2020-Ohio-3440. _____________________ SUPREME COURT OF OHIO

O’CONNOR, C.J. {¶ 1} In this appeal, we consider whether appellant, Acuity, an insurer, owes a duty to defend its insured, appellee, Masters Pharmaceutical, Inc. (“Masters”), in several lawsuits brought by cities and counties in West Virginia, Michigan, and Nevada (“the governments”) for economic losses caused by the opioid epidemic. The dramatic increase in the acceptance and use of highly addictive prescription opioids to treat chronic pain in recent years has contributed to the hundreds of thousands of opioid-related overdoses in the United States—now commonly referred to as the opioid-overdose epidemic. Centers for Disease Control and Prevention, Prescription Opioids, https://www.cdc.gov/opioids /basics/prescribed.html (accessed Apr. 27, 2022) [https://perma.cc/47KE-UGY9]; Centers for Disease Control and Prevention, Understanding the Opioid Overdose Epidemic, https://www.cdc.gov/opioids/basics/epidemic.html (accessed Apr. 27, 2022) [https://perma.cc/Q96N-2DA2]. The underlying lawsuits represent a growing number of actions initiated by governmental entities against opioid manufacturers, distributors, and retailers for their alleged improper marketing and inappropriate distributing of prescription opioids across the country. {¶ 2} Masters purchased several commercial general liability insurance policies from Acuity, and those policies impose on Acuity a duty to defend the insured against any suit seeking “damages because of bodily injury.” The trial court concluded that Acuity does not owe Masters a duty to defend it in the underlying suits, because the governments seek damages for their own economic losses. The First District Court of Appeals disagreed, finding that some of the governments’ economic losses are arguably “because of bodily injury,” and reversed the trial court’s judgment. Because we conclude that Acuity does not owe Masters a duty to defend, we reverse the judgment of the court of appeals and reinstate the trial court’s entry of summary judgment in favor of Acuity.

2 January Term, 2022

Relevant Background {¶ 3} Masters was a wholesale distributor of pharmaceutical products, and as part of its business, Masters filled and shipped orders of prescription opioids to pharmacies around the country.1 Twenty-two cities and counties in West Virginia, Michigan, and Nevada have sued Masters,2 as well as several pharmaceutical manufacturers, other distributors, and retailers. These underlying suits are substantially similar to each other and share common allegations and claims against Masters. The governments allege that Masters failed to monitor and report suspicious orders of prescription opioids and to implement measures to prevent the filling of improper prescriptions and that it thereby failed to maintain effective controls against the diversion of prescription opioids into the illicit market in violation of federal and state laws. The governments claim that Masters’s conduct “greatly contributed to the vast increase in opioid overuse and addiction” and caused “a public-health and law-enforcement crisis” in their respective communities. Based on these allegations, the governments assert claims for public nuisance, negligence, and, in a majority of the complaints, violations of the Racketeer Influenced and Corrupt Organization (“RICO”) Act, among other laws. They allege that Masters’s conduct contributed to the opioid epidemic that continues to plague their communities, resulting in the governments’ suffering economic losses, such as increased law-enforcement expenses, judicial expenditures, prison and public-works costs, emergency and medical-care-services costs, substance-abuse-treatment expenses, and lost economic opportunity. {¶ 4} Between July 26, 2010, and July 26, 2018, Masters purchased eight commercial general liability insurance policies from Acuity (each policy covering

1. As of January 1, 2018, Masters is a shell company and is no longer in operation.

2. The majority of these actions have been consolidated and transferred to a federal multidistrict- litigation court in the Northern District of Ohio as part of the national prescription-opioid litigation.

3 SUPREME COURT OF OHIO

one year). The policies state that under certain circumstances, Acuity has a duty to defend Masters against lawsuits seeking “damages because of bodily injury” and a duty to indemnify Masters for damages it may be legally obligated to pay. Acuity filed an action in the Hamilton County Court of Common Pleas for a declaratory judgment that it owed no duty to defend or indemnify Masters in the underlying suits. Masters counterclaimed for a declaration that Acuity owed both duties. {¶ 5} Both parties moved for summary judgment. In support of its motion, Acuity argued that the underlying suits do not fall within the policy coverage, because the governments seek damages for their own economic injury, not for any bodily injury, and because Masters knew of the opioid epidemic prior to purchasing the policies from Acuity. Masters countered that the policies provide coverage because the governments seek, at least in part, “damages because of bodily injury,” such as medical and treatment costs they have incurred because of opioid addiction and overdoses sustained by their citizens. {¶ 6} The trial court ultimately agreed with Acuity for two reasons. First, it concluded that the complaints in the underlying suits do not seek “damages because of bodily injury,” because the governments seek damages solely for their own economic loss, not damages for any citizen’s opioid addiction. And second, it found that Masters knew prior to the initial policy period of the alleged “bodily injury”—i.e., prescription opioid addiction—thereby precluding coverage under the policies’ loss-in-progress provisions. It accordingly granted Acuity’s motion for summary judgment, denied Masters’s motion for summary judgment, and declared that Acuity did not owe a duty to defend or indemnify Masters in the underlying suits. {¶ 7} Masters appealed and argued that the trial court erred in determining that Acuity had no duty to defend it in the underlying suits. The First District agreed and reversed the trial court’s judgment. It concluded that the policies expressly provide for organizations, like the governments in the underlying suits, to claim

4 January Term, 2022

“economic damages, as long as the damages occurred because of bodily injury.” 2020-Ohio-3440, ¶ 17.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
2022 Ohio 3092, 205 N.E.3d 460, 169 Ohio St. 3d 387, Counsel Stack Legal Research, https://law.counselstack.com/opinion/acuity-v-masters-pharmaceuticals-inc-ohio-2022.